Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in AdultsGlobeNewsWire • 07/11/23
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of JulGlobeNewsWire • 07/03/23
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United StatesGlobeNewsWire • 06/29/23
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial ProgramGlobeNewsWire • 06/15/23
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult SubjectsGlobeNewsWire • 06/13/23
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/22/23
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023GlobeNewsWire • 05/19/23
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/15/23
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to DeclineZacks Investment Research • 05/04/23
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023GlobeNewsWire • 05/04/23
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas' Short-Form Human Complement Factor HGlobeNewsWire • 04/24/23
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/30/23
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/29/23
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023GlobeNewsWire • 03/22/23
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical TrialGlobeNewsWire • 03/16/23
Journey Medical Corporation to Participate in the 35th Annual ROTH ConferenceGlobeNewsWire • 03/07/23
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRGlobeNewsWire • 02/16/23
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with TriplexGlobeNewsWire • 02/15/23
Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 02/10/23
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 02/08/23
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)Accesswire • 01/31/23
Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial OfficerGlobeNewsWire • 01/20/23
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular RosaceaGlobeNewsWire • 01/10/23